Pfizer Inc. (PFE)
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
Pfizer: Why I'm Still Expecting A Massive Rebound
Pfizer Inc. remains a Buy with 55%+ upside potential over two years, driven by a robust pipeline and undervalued forward earnings. PFE's Q1 2026 results beat estimates, with non-COVID sales up 7% YoY and strong contributions from Seagen and new product launches. Key catalysts include the potential blockbuster GLP-1 candidate berobenatide, aggressive oncology growth, and patent settlements extending revenue streams.
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees
Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses.
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
At $25.60, Pfizer (NYSE:PFE | PFE Price Prediction) sits in Hold territory on Wall Street's consensus.
Prediction: Pfizer Stock Will Double on This Date
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1.
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Pfizer (PFE) reports positive mid-stage trial data for berobenatide, aiming to be the first GLP-1 obesity therapy with monthly dosing. PFE plans up to 10 Phase 3 trials for berobenatide, targeting long-term obesity management and related conditions.
